| Objective: renal cell carcinoma, bladder urothelial carcinoma are the most commonmalignant tumor of urinary system, incidence of a disease and mortality has increasedyear by year trend. They happen and transfer of development is a complex dynamicprocess, involving many factors related to cancer of participation and regulation,pathogenesis is still not clear. The discovery of the molecular genetics, for looking fornew and effective in the treatment of their method provides theoretical basis. In recentyears more research Galectin-3widely present in normal tissue and tumor tissue,participate in multiple physiological and pathological process, including cell growthand apoptosis, cell adhesion and angiogenesis, and tumor invasion and metastasis, etc.In order to further understand the research Galectin-3in renal cell carcinoma andbladder urothelial carcinoma of the role of the discussion Galectin-3with renal cellcarcinoma and bladder urothelial carcinoma of clinical pathology meaning, may forrenal cell carcinoma and bladder urothelial carcinoma of early diagnosis andtreatment to provide the theory basis.Methods: choose from anhui medical university provincial hospital affiliatedpathologists2007to2011archive renal cell carcinoma piece of83patients and2006samples in2011to in archive bladder urothelial carcinoma piece of specimen67cases.In another18cases of tumor more than2cm away from normal kidney tissues and l2cases2cm above the tumor away from normal bladder tissue as a control group. Allthe specimens are complete clinical pathology diagnosis material, patients were not doany treatment before. By immunohistochemical method to detect SP Galectin-3in83patients with different pathological type renal cell carcinoma and18patients withnormal renal tissue of expression. Combined with clinical pathologic data, analyzingthe renal cell carcinoma of the relationship between the clinical and pathological features; By immunohistochemical method, SP Galectin-3and MMP-2testing in67patients with bladder urothelial carcinoma and12cases of normal bladder tissue ofexpression, and CD34immunohistochemical stains count number tumor blood essels.Combined with clinical pathologic data, analyzing the bladder urothelial carcinoma ofthe relationship between the clinical and pathological features.Results:1. Galectin-3in different pathological type renal cell carcinoma and normalrenal tissue of expression:(1): Galectin-3in renal cell carcinoma of the positive expression rate was50.60%(42/83), normal renal tissues in the positive expression rate was11.11%(2/18).Difference was statistically significant (P <0.05).(2): Galectin-3in clear cell carcinoma of the positive expression rate was38.89%(21/54), in the papillary cell carcinoma of the positive expression rate was68.42%(13/19), in chromophobe carcinoma of the positive expression rate was80.00%(8/10).Galectin-3in the papillary cell carcinoma and chromophobe carcinoma was higherthan the express clear cell carcinoma, the difference was statistically significant (P <0.05).(3): as the clinical stages and pathology classification of increased Galectin-3is theexpression of the increasing trend, the difference was statistically significant (P <0.05); A lymph node metastasis are more without the express transfer rate is high, thedifference was statistically significant (P <0.05); Patient sex, age and the tumordiameter no difference, not statistically significant (P>0.05).2. Galectin-3, MMP-2in the bladder urothelial carcinoma and normal bladder tissueof expression:(1) bladder urothelial carcinoma in Galectin-3and MMP-2positive expression rateand MVD significantly higher than normal bladder tissue, significant statisticallysignificant difference (P <0.05), Galectin-3and MMP-2positively related to express(P <0.05).(2) Galectin-3and MMP-2in the bladder urothelial carcinoma of the bladderexpression and urinary epithelial cancer pathological types, the clinical stages, lymphnode metastasis and recurrence relevant (P <0.05); With the patient and gender, age and tumor diameter irrelevant (P>0.05).Conclusion: Galectin-3high expression in renal cell carcinoma, especially papillarycell carcinoma and chromophobe carcinoma closely related to the occurrence anddevelopment, of renal cell carcinoma of the differential diagnosis and treatmentprovides reference index; Galectin-3and MMP-2in the bladder urothelial carcinomaincreased and the expression in the positive correlation between; Both high expressionand its synergy in bladder may be plays an important role in the metastasis,happening, development and recurrence of bladder urothelial carcinoma. |
PDF Full Text Request